Eli Lilly to join lawsuit over GLP-1 shortage
CNBC on MSN16d
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...
Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.
Eli Lilly is partnering with the Flatiron-based ... telehealth provider for a diagnosis and prescription, skipping an in-person trip to the doctor or pharmacy. Companies including Pfizer and ...
Hosted on MSN2d
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should KnowEli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback